Bank of New York Mellon’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-187,963
| Closed | -$7.08M | – | 4550 |
|
|
2021
Q1 | $7.08M | Buy |
187,963
+13,967
| +8% | +$348K | ﹤0.01% | 2275 |
|
|
2020
Q4 | $2.96M | Buy |
173,996
+52,443
| +43% | +$657K | ﹤0.01% | 2620 |
|
|
2020
Q3 | $572K | Sell |
121,553
-1,973
| -2% | -$10K | ﹤0.01% | 3424 |
|
|
2020
Q2 | $753K | Sell |
123,526
-16,616
| -12% | -$68.4K | ﹤0.01% | 3262 |
|
|
2020
Q1 | $318K | Buy |
140,142
+10,788
| +8% | +$45.8K | ﹤0.01% | 3578 |
|
|
2019
Q4 | $594K | Sell |
129,354
-28,591
| -18% | -$113K | ﹤0.01% | 3505 |
|
|
2019
Q3 | $612K | Sell |
157,945
-2,450
| -2% | -$13.4K | ﹤0.01% | 3426 |
|
|
2019
Q2 | $967K | Sell |
160,395
-10,577
| -6% | -$101K | ﹤0.01% | 3234 |
|
|
2019
Q1 | $2.29M | Sell |
170,972
-219
| -0.1% | -$2.5K | ﹤0.01% | 2710 |
|
|
2018
Q4 | $1.59M | Sell |
171,191
-1,040
| -0.6% | -$12.4K | ﹤0.01% | 2846 |
|
|
2018
Q3 | $2.4M | Buy |
172,231
+12,076
| +8% | +$180K | ﹤0.01% | 2747 |
|
|
2018
Q2 | $2.53M | Sell |
160,155
-8,586
| -5% | -$150K | ﹤0.01% | 2728 |
|
|
2018
Q1 | $2.9M | Buy |
168,741
+18,496
| +12% | +$361K | ﹤0.01% | 2622 |
|
|
2017
Q4 | $3.29M | Sell |
150,245
-75,178
| -33% | -$2.42M | ﹤0.01% | 2565 |
|
|
2017
Q3 | $9.22M | Sell |
225,423
-2,927
| -1% | -$91.9K | ﹤0.01% | 2030 |
|
|
2017
Q2 | $6.88M | Buy |
228,350
+4,474
| +2% | +$140K | ﹤0.01% | 2162 |
|
|
2017
Q1 | $8.09M | Sell |
223,876
-629
| -0.3% | -$27.7K | ﹤0.01% | 2079 |
|
|
2016
Q4 | $11.3M | Buy |
224,505
+80,047
| +55% | +$4.21M | ﹤0.01% | 1899 |
|
|
2016
Q3 | $7.58M | Sell |
144,458
-4,603
| -3% | -$220K | ﹤0.01% | 2011 |
|
|
2016
Q2 | $6.16M | Buy |
149,061
+17,694
| +13% | +$770K | ﹤0.01% | 2103 |
|
|
2016
Q1 | $5.34M | Buy |
131,367
+9,435
| +8% | +$324K | ﹤0.01% | 2153 |
|
|
2015
Q4 | $5.06M | Buy |
121,932
+10,113
| +9% | +$339K | ﹤0.01% | 2210 |
|
|
2015
Q3 | $1.72M | Sell |
111,819
-13,149
| -11% | -$283K | ﹤0.01% | 2830 |
|
|
2015
Q2 | $3.1M | Buy |
124,968
+37,921
| +44% | +$845K | ﹤0.01% | 2641 |
|
|
2015
Q1 | $1.99M | Buy |
87,047
+23,051
| +36% | +$582K | ﹤0.01% | 2867 |
|
|
2014
Q4 | $1.73M | Sell |
63,996
-3,903
| -6% | -$67.2K | ﹤0.01% | 2965 |
|
|
2014
Q3 | $796K | Sell |
67,899
-1,741
| -3% | -$22K | ﹤0.01% | 3422 |
|
|
2014
Q2 | $1.08M | Buy |
69,640
+50,426
| +262% | +$723K | ﹤0.01% | 3269 |
|
|
2014
Q1 | $378K | Buy |
19,214
+7,825
| +69% | +$133K | ﹤0.01% | 3663 |
|
|
2013
Q4 | $191K | Buy |
+11,389
| New | +$142K | ﹤0.01% | 3864 |
|
Bank of New York Mellon's FPRX Position: Q2 2021 in Review
Bank of New York Mellon sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 187,963 shares — an estimated $7.08M sold.
Bank of New York Mellon first reported a position in FPRX in Q4 2013 and held it in 30 quarters. The position peaked at $11.3M in Q4 2016. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Bank of New York Mellon reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Bank of New York Mellon sold 187,963 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $7.08M.
- Bank of New York Mellon first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 30 quarters.
- Bank of New York Mellon's Five Prime Therapeutics, Inc. position peaked at $11.3M in Q4 2016.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Bank of New York Mellon's 13F filing for Q2 2021, filed 11 Aug 2021.